Free Trial

Mid Cap Stocks To Research - May 5th

Arcellx logo with Medical background
Image from MarketBeat Media, LLC.

Key Points

  • MarketBeat highlights seven mid-cap names to watch by recent dollar trading volume: Arcellx (ACLX), ProShares UltraPro Short QQQ (SQQQ), Cytokinetics (CYTK), Cipher Mining (CIFR), Direxion Daily MU Bull 2X (MUU), Direxion Daily TSLA Bull 2X (TSLL), and AXT (AXTI).
  • The group spans diverse sectors — clinical-stage biotech (Arcellx, Cytokinetics), semiconductor materials (AXT), bitcoin mining (Cipher Mining) and leveraged/short ETFs (SQQQ, MUU, TSLL) — implying varied risk and return profiles for investors.
  • These names were flagged for high recent trading activity among mid caps, underscoring liquidity and investor interest, but investors should weigh that against the higher volatility of leveraged ETFs and single-stock/sector exposure.
  • MarketBeat previews top five stocks to own in June.

Arcellx, ProShares UltraPro Short QQQ, Cytokinetics, Cipher Mining, Direxion Daily MU Bull 2X Shares, Direxion Daily TSLA Bull 2X Shares, and AXT are the seven Mid Cap stocks to watch today, according to MarketBeat's stock screener tool. Mid-cap stocks are shares of companies whose market capitalization typically falls between about $2 billion and $10 billion (exact cutoffs vary by index providers). They often combine higher growth potential than large-cap firms with greater stability than small-cap companies, offering a moderate risk–return profile for investors. Many investors include mid caps for diversification and long-term growth in a balanced portfolio. These companies had the highest dollar trading volume of any Mid Cap stocks within the last several days.

Arcellx (ACLX)

Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM).

Read Our Latest Research Report on ACLX

ProShares UltraPro Short QQQ (SQQQ)

ProShares UltraPro Short QQQ (the Fund) seeks daily investment results, which corresponds to three times the inverse of the daily performance of the NASDAQ-100 Index (the Index). The Index includes 100 of the non-financial domestic and international issues listed on National Association of Securities Dealers Automated Quotation (NASDAQ) Stock Market.

Read Our Latest Research Report on SQQQ

Cytokinetics (CYTK)

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.

Read Our Latest Research Report on CYTK

Cipher Mining (CIFR)

Read Our Latest Research Report on CIFR

Direxion Daily MU Bull 2X Shares (MUU)

Read Our Latest Research Report on MUU

Direxion Daily TSLA Bull 2X Shares (TSLL)

Read Our Latest Research Report on TSLL

AXT (AXTI)

AXT, Inc. designs, develops, manufactures, and distributes compound and single element semiconductor substrates. The company offers indium phosphide for use in data center connectivity using light/lasers, high-speed data transfer in data centers, 5G communications, fiber optic lasers and detectors, consumer devices, passive optical networks, silicon photonics, photonic integrated circuits, thermo-photovoltaics, RF amplifier and switching, infrared light-emitting diode (LEDS) motion control, lidar for robotics and autonomous vehicles, and infrared thermal imaging.

Read Our Latest Research Report on AXTI

Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Arcellx Right Now?

Before you consider Arcellx, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arcellx wasn't on the list.

While Arcellx currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Best Stocks to Own in 2026 Cover

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Spring 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines